https://www.selleckchem.com/pr....oducts/triptolide.ht
vely benign and transient profile of adverse events make LEV preferable as monotherapy in the pediatric population. The present study suggests that the high retention rates, high percentage of seizure reduction, the low discontinuation rate due to adverse events and inefficacy, and the relatively benign and transient profile of adverse events make LEV preferable as monotherapy in the pediatric population. In epilepsy, patients who receive appropriate care receive treatment that differs substantially from those that do not. Given the